Heartflow vs Travere Therapeutics
Heartflow (HTFL), health care, and Travere Therapeutics (TVTX), health care, side by side on market value, valuation, margins, balance sheet and price change. Higher and lower are marked; neither is called better.
Travere Therapeutics is worth $4.9B on the stock market and Heartflow $4.1B: Travere Therapeutics is valued at 19% more. Heartflow's operating margin in its latest fiscal year was -36.4% and Travere Therapeutics's -12.8%. Over the past year Heartflow's share price has moved +71.6% and Travere Therapeutics's +38.1%.
Key facts
- Heartflow market value
- $4.1B
- Travere Therapeutics market value
- $4.9B
- Heartflow P/E
- 70.3
- Heartflow revenue
- $176MFY to 2025-12-31
- Travere Therapeutics revenue
- $490.7MFY to 2025-12-31
- Superinvestors holding both
- 1
Market values as of .
| Measure | Heartflow | Travere Therapeutics |
|---|---|---|
| Sector | Health Care | Health Care |
| Country | ||
| Fiscal year ends | 2025-12-31 | 2025-12-31 |
| Size | ||
| Market cap | $4.1Blower | $4.9Bhigher |
| Revenue | $176Mlower | $490.7Mhigher |
| Earnings | -$116.8Mlower | -$25.5Mhigher |
| Employees | 843higher | 497lower |
| Total assets | $359.5Mlower | $605.2Mhigher |
| Valuation | ||
| P/E | 70.3 | — |
| P/S | 23.5higher | 10.0lower |
| P/B | 14.6lower | 217higher |
| Dividend yield | 0.00% | 0.00% |
| Profitability | ||
| Operating margin | -36.4%lower | -12.8%higher |
| Balance sheet | ||
| Net assets | $300.6Mhigher | $114.8Mlower |
| Total liabilities | $58.8Mlower | $490.4Mhigher |
| Total debt | — | — |
| Cash on hand | $44.8Mlower | $93Mhigher |
| Price change | ||
| Today | +0.45%lower | +2.82%higher |
| 1 year | +71.6%higher | +38.1%lower |
Market value, P/E, P/B, dividend yield and price changes are from live quotes (Yahoo Finance; prices may be delayed 15 minutes or more). Revenue, earnings, operating margin and the balance-sheet figures are from each company's latest annual report filed with the SEC (collected 2026-11-12); a company that reports in another currency is converted to US dollars at the exchange rate of that day. P/S sets today's market value against the latest fiscal year's revenue. “Higher” and “lower” compare the two numbers only; a higher P/E or more debt is not better. Dividend yield and P/B are shown only for companies based in the US. A dash means no figure is on file.
Which superinvestors hold them
From each tracked investor's latest 13F filing. A 13F lists long positions in US-listed shares at a quarter end, filed up to 45 days later.
Both (1)
- Polen Capital team<0.1% / <0.1%
Travere Therapeutics only (0)
None of the tracked investors.
Percentages are each holding's share of that investor's reported portfolio (under "Both": Heartflow / Travere Therapeutics). Who owns HTFL · Who owns TVTX
More on Heartflow
Further comparisons
Heartflow against its closest peers
Travere Therapeutics against its closest peers
Learn
Questions and answers
Which is bigger, Heartflow or Travere Therapeutics?
By market value, Travere Therapeutics is the larger: $4.9B against $4.1B for Heartflow. By revenue in its latest fiscal year, Travere Therapeutics is the larger: $490.7M against $176M for Heartflow.
Which has the higher operating margin?
Travere Therapeutics: -12.8%, against -36.4% for Heartflow. Operating margin is operating income as a share of revenue in the latest fiscal year.
Which has the higher dividend yield?
Neither: both stand at 0.00%. Dividend yield is the last twelve months' dividends as a share of today's share price.
Which superinvestors own both Heartflow and Travere Therapeutics?
In their latest 13F filings, Polen Capital team holds both.
Cite this page
Funkfolio, “Heartflow vs Travere Therapeutics”, data as of 17 November 2026. https://funkfolio.com/compare/htfl-vs-tvtx
Underlying data: Yahoo Finance quotes; SEC annual reports collected 2026-11-12; 13F filings.